Martine Piccart
YOU?
Author Swipe
View article: The Breast International Group (BIG) Patient Partnership: Embedding meaningful patient involvement in the design and conduct of breast cancer clinical research
The Breast International Group (BIG) Patient Partnership: Embedding meaningful patient involvement in the design and conduct of breast cancer clinical research Open
Involving those with a lived experience of the relevant condition in the design of clinical research ensures that studies address real-world needs and priorities, enabling more relevant, ethical, and impactful outcomes. In 2019, the Breast…
View article: Corrigendum to “Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial” [The Breast 83 (2025) 104547]
Corrigendum to “Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial” [The Breast 83 (2025) 104547] Open
View article: Neoadjuvant immune-modulating SBRT and anti-CD73 to increase response to anti-PD-L1 and chemotherapy in early ER+/HER2- breast cancer: primary endpoint and translational results from the randomized Neo-CheckRay trial
Neoadjuvant immune-modulating SBRT and anti-CD73 to increase response to anti-PD-L1 and chemotherapy in early ER+/HER2- breast cancer: primary endpoint and translational results from the randomized Neo-CheckRay trial Open
Patients with oestrogen receptor-positive (ER+), HER2-negative, early breast cancer (BC) have low pathological complete response (pCR) rates following neoadjuvant chemotherapy (NACT). Phase 3 trials showed that adding an anti-PD-1 immune c…
View article: Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial
Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial Open
ClinicalTrials.gov number NCT02308085.
View article: Prognostication and treatment predictions for estrogen receptor positive early-stage breast cancer: incorporating the 70-gene signature into the PREDICT prognostication model
Prognostication and treatment predictions for estrogen receptor positive early-stage breast cancer: incorporating the 70-gene signature into the PREDICT prognostication model Open
View article: The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study
The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study Open
View article: ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)
ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0) Open
View article: 226P Long-term outcomes of patients with HER2-positive breast cancer and rare special histologies in the ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)]
226P Long-term outcomes of patients with HER2-positive breast cancer and rare special histologies in the ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] Open
View article: Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial
Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial Open
View article: Continuous replenishment of the dysfunctional CD8 T cell axis is associated with response to chemoimmunotherapy in advanced breast cancer
Continuous replenishment of the dysfunctional CD8 T cell axis is associated with response to chemoimmunotherapy in advanced breast cancer Open
View article: Redefining the role of anthracyclines in early breast cancer treatment
Redefining the role of anthracyclines in early breast cancer treatment Open
Anthracyclines have long been a cornerstone of early breast cancer treatment, contributing to significant reductions in recurrence and improvements in survival. Concerns about long-term toxicities, particularly cardiotoxicity and secondary…
View article: Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer Open
Importance Triple-negative breast cancer is an aggressive subtype with a high incidence in young patients, a high incidence in non-Hispanic Black women, and a high risk of progression to metastatic cancer, a devastating sequela with a 12- …
View article: Editorial Expression of Concern: The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts
Editorial Expression of Concern: The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts Open
View article: 2O TILs and PD-L1 early dynamics in the randomized Neo-CheckRay phase II trial evaluating neo-adjuvant immuno-radiation and adenosine pathway blockade for early-stage, high risk ER+/HER2- breast cancer (BC)
2O TILs and PD-L1 early dynamics in the randomized Neo-CheckRay phase II trial evaluating neo-adjuvant immuno-radiation and adenosine pathway blockade for early-stage, high risk ER+/HER2- breast cancer (BC) Open
View article: Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial
Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial Open
View article: Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers Open
View article: Summary of quality of life in the ASCENT phase 3 clinical trial for people with metastatic triple-negative breast cancer
Summary of quality of life in the ASCENT phase 3 clinical trial for people with metastatic triple-negative breast cancer Open
Participants treated with sacituzumab govitecan had a higher likelihood of living longer and delayed progression (worsening) of their cancer. Participants also had a better overall quality of life, which was maintained (did not get worse) …
View article: Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer Open
A higher frequency…", the order of the percentage of patients in the SG and TPC arms who discontinued treatment due to adverse events in the ASCENT trial has been written backwards.Therefore, on page 5, values "26% and 22%, respectively" h…
View article: Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy
Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy Open
PURPOSE We investigated time to pregnancy, efficacy and safety of fertility preservation, and assisted reproductive technologies (ARTs) in women with early hormone receptor–positive breast cancer (BC) desiring future pregnancy. PATIENTS AN…
View article: Emerging treatments in HER2-positive advanced breast cancer: Keep raising the bar
Emerging treatments in HER2-positive advanced breast cancer: Keep raising the bar Open
View article: 189P The impact of high body mass index (BMI) on the safety and efficacy of sacituzumab govitecan (SG) in patients (pts) with metastatic triple-negative breast cancer (mTNBC) from ASCENT
189P The impact of high body mass index (BMI) on the safety and efficacy of sacituzumab govitecan (SG) in patients (pts) with metastatic triple-negative breast cancer (mTNBC) from ASCENT Open
SG is a Trop-2–directed antibody-drug conjugate (ADC) approved in multiple countries for the treatment of relapsed or refractory mTNBC. In the phase III ASCENT study (n = 529), significantly longer PFS (hazard ratio [HR], 0.43; 95% CI, 0.3…
View article: Correction: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium
Correction: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium Open
View article: Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression Open
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. …
View article: Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions
Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions Open
View article: Molecular Imaging in Breast Cancer
Molecular Imaging in Breast Cancer Open
David Mankoff, MD, PhD, the Matthew J. Wilson Professor of Research Radiology at the University of Pennsylvania Perelman School of Medicine (Philadelphia) and an associate editor for The Journal of Nuclear Medicine ( JNM ), talked with bre…
View article: Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial)
Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial) Open
Efficacy of the human epidermal growth factor receptor (HER)2-targeting trastuzumab emtansine (T-DM1) in breast cancer (BC) relies on HER2 status determined by immunohistochemistry or fluorescence in-situ hybridization. Heterogeneity in HE…
View article: Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial Open
Correction to: Nature Communications 10.1038/s41467-023-42744-y, published online 02 November 2023. In the “Discussion” section of the original manuscript, the authors reported information and data related to an unpublished work (Metoikido…
View article: Progression-free survival assessment by local investigators versus blinded independent central review in randomized clinical trials in metastatic breast cancer: A systematic review and meta-analysis
Progression-free survival assessment by local investigators versus blinded independent central review in randomized clinical trials in metastatic breast cancer: A systematic review and meta-analysis Open
View article: First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial
First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial Open
Background Luminal B breast cancer (BC) presents a worse prognosis when compared with luminal A BC and exhibits a lower sensitivity to chemotherapy and a lower immunogenicity in contrast to non-luminal BC subtypes. The Neo-CheckRay clinica…
View article: The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study
The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study Open